Idiopathic inflammatory myopathies

Neurologic Clinics

Volumn 32, Issue 3, 2014, Pages 595-628

  Dimachkie, Mazen M ^a   Barohn, Richard J ^a   Amato, Anthony A ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinical presentation; Dermatomyositis; Diagnosis; Inclusion body myositis; Necrotizing myopathy; Pathology; Polymyositis; Treatment

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOGLOBULIN; JO 1 ANTIBODY; METHOTREXATE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; AUTOIMMUNE DISEASE; AUTOIMMUNE NECROTIZING MYOPATHY; CANCER SCREENING; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ASSOCIATION; ELECTROMYOGRAM; ELECTROPHYSIOLOGY; HEART DISEASE; HISTOPATHOLOGY; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; LUNG FUNCTION TEST; MUSCLE WEAKNESS; MYOPATHY; MYOSITIS; PATHOGENESIS; PATIENT MONITORING; PHENOTYPE; PHYSIOTHERAPY; POLYARTHRITIS; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE; AUTOIMMUNE DISEASES; COMPLICATION; FEMALE; IMMUNOLOGY; MALE; MYOSITIS, INCLUSION BODY;

AUTOIMMUNE DISEASES; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; MUSCLE WEAKNESS; MYOSITIS; MYOSITIS, INCLUSION BODY;

EID: 84904305136     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2014.04.007     Document Type: Review

References (148)

1. van der Meulen M.F., Bronner I.M., Hoogendijk J.E., et al. Polymyositis: an overdiagnosed entity. Neurol 2003, 61:316-321.
2. Chahin N., Engel A.G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurol 2008, 70(6):418-424.
3. Tan J.A., Roberts-Thomson P.J., Blumbergs P., et al. Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. Int J Rheum Dis 2013, 16(3):331-338.
4. Kuo C.F., See L.C., Yu K.H., et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 2011, 165(6):1273-1279.
5. Regardt M., Welin Henriksson E., Alexanderson H., et al. Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study. Rheumatology (Oxford) 2011, 50(3):578-585.
6. Quinter S.D., Chiu Y.E., Lyon V.B., et al. Inverse Gottron's papules: an unusual cutaneous manifestation of juvenile dermatomyositis. Pediatr Dermatol 2012, 29(5):641-644. 10.1111/j.1525-1470.2011.01585.x.
7. Schmeling H., Stephens S., Goia C., et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology (Oxford) 2011, 50(5):885-893.
8. Shirani Z., Kucenic M.J., Carroll C.L., et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol 2004, 29:273-276.
9. Hundley J.L., Carroll C.L., Lang W., et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. JAm Acad Dermatol 2006, 54:217-220.
10. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). NEngl J Med 1975, 292(7):344-347.
11. Bohan A., Peter J.B. Polymyositis and dermatomyositis (second of two parts). NEngl J Med 1975, 292:403-407.
12. Targoff I.N., Miller F.W., Medsger T.A., et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997, 9(6):527-535.
13. Hoogendijk J.E., Amato A.A., Lecky B.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004, 14(5):337-345.
14. Amato A.A., Griggs R.C. Unicorns, dragons, polymyositis and other mythical beasts. Neurol 2003, 61:288-289.
15. Amato A.A., Barohn R.J. Idiopathic inflammatory myopathies. Neurol Clin 1997, 15:615-648.
16. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
17. Pal S., Sanyal D. Jaw muscle weakness: a differential indicator of neuromuscular weakness-preliminary observations. Muscle Nerve 2011, 43(6):807-811.
18. Ellis E., Ann Tan J., Lester S., et al. Necrotizing myopathy: clinicoserologic associations. Muscle Nerve 2012, 45(2):189-194.
19. Suzuki S., Ohta M., Shimizu Y., et al. Anti-signal recognition particle myopathy in the first decade of life. Pediatr Neurol 2011, 45(2):114-116.
20. Muzyka I., Barohn R.J., Dimachkie M., et al. Necrotizing autoimmune statin -associated myopathy. JClin Neuromuscul Dis 2011, 12(3):17.
21. Grable-Esposito P., Katzberg H.D., Greenberg S.A., et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41(2):185-190.
22. Niewold T.B., Wu S.C., Smith M., et al. Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics 2011, 127(5):e1239-e1246.
23. Tymms K.E., Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. JRheumatol 1985, 12(6):1140-1148.
24. Marie I., Hatron P.Y., Dominique S., et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011, 63(11):3439-3447.
25. Hochberg M.C., Feldman D., Stevens M.B., et al. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. JRheumatol 1984, 11(5):663-665.
26. Maoz C.R., Langevitz P., Livneh A., et al. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 1998, 27(5):319-324.
27. Sigurgeirsson B., Lindelöf B., Edhag O., et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. NEngl J Med 1992, 326(6):363-367.
28. Lakhanpal S., Bunch T.W., Ilstrup D.M., et al. Polymyositis-dermatomyositis and malignant lesions: does an association exist?. Mayo Clin Proc 1986, 61(8):645-653.
29. Scaling S.T., Kaufman R.H. Patten BM Dermatomyositis and female malignancy. Obstet Gynecol 1979, 54(4):474-477.
30. Rider L.G., Miller F.W. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997, 23(3):619-655.
31. Chen Y.J., Wu C.Y., Huang Y.L., et al. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010, 12(2):R70.
32. Needham M., Fabian V., Knezevic W., et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007, 17(2):194-200.
33. Wang Y., Barohn R.J., McVey A.L., et al. Necrotizing myopathy: a unique immune-mediated myopathy. JChild Neurol 2004, 19:207.
34. Miller T., Al-Lozi M.T., Lopate G., et al. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. JNeurol Neurosurg Psychiatry 2002, 73(4):420-428.
35. Zöller B., Li X., Sundquist J., et al. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS One 2012, 7(3):e33442.
36. Eimer M.J., Brickman W.J., Seshadri R., et al. Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis. JPediatr 2011, 159(5):795-801.
37. Hill C.L., Zhang Y., Sigurgeirsson B., et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001, 357(9250):96-100.
38. Marie I., Guillevin L., Menard J.F., et al. Hematological malignancy associated with polymyositis and dermatomyositis. Autoimmun Rev 2012, 11(9):615-620.
39. Sparsa A., Liozon E., Herrmann F., et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 2002, 138(7):885-890.
40. Titulaer M.J., Soffietti R., Dalmau J., et al. European Federation of Neurological Societies. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011, 18(1):19-e3.
41. Marie I., Josse S., Hatron P.Y., et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013, 65(5):800-808.
42. Labirua A., Lundberg I.E. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 2010, 22(6):633-638.
43. Marie I., Josse S., Decaux O., et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012, 11(10):739-745.
44. Marie I., Josse S., Decaux O., et al. Outcome of anti-PL12 positive patients with antisynthetase syndrome. Presse Med 2013, 42(6 Pt 1):e153-e158.
45. Mimori T., Nakashima R., Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 2012, 14(3):264-274.
46. Hall J.C., Casciola-Rosen L., Samedy L.A., et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013, 65(8):1307-1315.
47. Gono T., Kawaguchi Y., Sugiura T., et al. Interferon-induced helicase (IFIH1) polymorphism with systemic lupus erythematosus and dermatomyositis/polymyositis. Mod Rheumatol 2010, 20(5):466-470.
48. Fathi M., Barbasso Helmers S., Lundberg I.E. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. JIntern Med 2011, 271(6):589-597. 10.1111/j.1365-2796.2011.02459.x.
49. Gono T., Kawaguchi Y., Sugiura T., et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford) 2010, 49(10):1878-1881.
50. Tanizawa K., Handa T., Nakashima R., et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 2013, 107(5):745-752.
51. López De Padilla C.M., McNallan K.T., Crowson C.S., et al. BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. JRheumatol 2013, 40(3):294-302.
52. Filková M., Senolt L., Vencovský J. The role of resistin in inflammatory myopathies. Curr Rheumatol Rep 2013, 15(6):336.
53. Ichimura Y., Matsushita T., Hamaguchi Y., et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012, 71(5):710-713.
54. Nakajima A., Yoshino K., Soejima M., et al. High Frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis. Rheumatol Int 2011, 32(7):2057-2061.
55. Vincze M., Molnár P.A., Tumpek J., et al. An unusual association: anti-Jo1 and anti-SRP antibodies in the serum of a patient with polymyositis. Clin Rheumatol 2010, 29(7):811-814.
56. Sugie K., Tonomura Y., Ueno S. Characterization of Dermatomyositis with Coexistence of Anti-Jo-1 and Anti-SRP Antibodies. Intern Med 2012, 51(7):799-802.
57. Joffe M.M., Love L.A., Leff R.L., et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993, 94(4):379-387.
58. Kunimasa K., Arita M., Nakazawa T., et al. The clinical characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis/dermatomyositis. Intern Med 2012, 51(24):3405-3410.
59. Kaji K., Fujimoto M., Hasegawa M., et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007, 46:25-28.
60. Rider L.G., Shah M., Mamyrova G., Childhood Myositis Heterogeneity Collaborative Study Group, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013, 92(4):223-243.
61. Ikeda N., Takahashi K., Yamaguchi Y., et al. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. JDermatol 2011, 38(10):973-979.
62. Tanizawa K., Handa T., Nakashima R., et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 2011, 105(9):1380-1387.
63. Kobayashi I., Okura Y., Yamada M., et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. JPediatr 2011, 158(4):675-677.
64. Suzuki S. Anti-SRP myopathy. Rinsho Shinkeigaku 2011, 51(11):961-963. [in Japanese].
65. Kao A.H., Lacomis D., Lucas M., et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004, 50:209-215.
66. Hanisch F., Müller T., Stoltenburg G., et al. Unusual manifestations in two cases of necrotizing myopathy associated with SRP-antibodies. Clin Neurol Neurosurg 2012, 114(7):1104-1106.
67. Christopher-Stine L., Casciola-Rosen L.A., Hong G., et al. Anovel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010, 62(9):2757-2766.
68. Degardin A., Morillon D., Lacour A., et al. Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skeletal Radiol 2010, 39(12):1219-1227.
69. Kissel J.T., Mendell J.R., Rammoha K.W. Microvascular deposition of complement membrane attack complex in dermatomyositis. NEngl J Med 1986, 314:329-334.
70. Emslie-Smith A.M., Engel A.G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990, 27:343-356.
71. Pestronk A., Schmidt R.E., Choksi R. Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle Nerve 2010, 42(1):53-61.
72. Greenberg S.A., Bradshaw E.M., Pinkus J.L., et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005, 65(11):1782-1787.
73. Uchino M., Yamashita S., Uchino K., et al. Muscle biopsy findings predictive of malignancy in rare infiltrative dermatomyositis. Clin Neurol Neurosurg 2013, 115(5):603-606.
74. Nandakumar S., Miller C.W., Kumaraguru U. Tregulatory cells: an overview and intervention techniques to modulate allergy outcome. Clin Mol Allergy 2009, 7:5.
75. Antiga E., Kretz C.C., Klembt R., et al. Characterization of regulatory T cells in patients with dermatomyositis. JAutoimmun 2010, 35(4):342-350.
76. Waschbisch A., Schwab N., Ruck T., et al. FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. JNeuroimmunol 2010, 225(1-2):137-142.
77. Gendek-Kubiak H., Gendek E.G. Fascin-expressing dendritic cells dominate in polymyositis and dermatomyositis. JRheumatol 2013, 40(2):186-191.
78. De Visser M., Emslie-Smith A.M., Engel A.G. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. JNeurol Sci 1989, 94(1-3):181-192.
79. Zhou X., Dimachkie M.M., Xiong M., et al. cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Med Sci Monit 2004, 10(7):BR191-BR197.
80. Walsh R.J., Kong S.W., Yao Y., et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007, 56(11):3784-3792.
81. Bilgic H., Ytterberg S.R., Amin S., et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009, 60(11):3436-3446.
82. Liao A.P., Salajegheh M., Nazareno R., et al. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 2011, 70(5):831-836.
83. Wong D., Kea B., Pesich R., et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One 2012, 7(1):e29161.
84. Salaroli R., Baldin E., Papa V., et al. Validity of internal expression of the major histocompatibility complex class I in the diagnosis of inflammatory myopathies. JClin Pathol 2012, 65(1):14-19.
85. Greenberg S.A., Pinkus G.S., Amato A.A., et al. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007, 35(1):17-23.
86. Greenberg S.A., Pinkus J.L., Pinkus G.S., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57(5):664-678.
87. Greenberg S.A., Higgs B.W., Morehouse C., et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 2012, 13(3):207-213. 10.1038/gene.2011.61.
88. Emslie-Smith A.M., Engel A.G. Necrotizing myopathy with pipestem capillaries, microvascular deposition of complement membrane attack complex (MAC), and minimal cellular infiltration. Neurol 1991, 41:936-939.
89. Bronner I.M., Hoogendijk J.E., Wintzen A.R., et al. Necrotizing myopathy, an unusual presentation of a steroid-responsive myopathy. JNeurol 2003, 250:480-485.
90. Mammen A.L., Chung T., Christopher-Stine L., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011, 63(3):713-721. 10.1002/art.30156.
91. Amato A.A., Barohn R.J. Inclusion body myositis: old and new concepts. JNeurol Neurosurg Psychiatry 2009, 80(11):1186-1193.
92. Bunch T.W., Worthington J.W., Combs J.J., et al. Azathioprine with prednisone for polymyositis. Ann Intern Med 1980, 92(3):365-369.
93. Miller F.W., Leitman S.F., Cronin M., et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. NEngl J Med 1992, 326:1380-1384.
94. Dalakas M.C., Illa I., Dambrosia J.M., et al. Acontrolled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. NEngl J Med 1993, 329(27):1993-2000.
95. Miller J., Walsh Y., Saminaden S., et al. Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. JNeurol Sci 2002, 199(Suppl 1):S53.
96. Vencovsky J., Jarosova K., Machacek S., et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000, 29(2):95-102.
97. Villalba L., Hicks J.E., Adams E.M., et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998, 41(3):392-399.
98. Muscle Study Group Arandomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011, 70(3):427-436.
99. van de Vlekkert J., Hoogendijk J.E., de Haan R.J., et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 2010, 20(6):382-389.
100. Rodd C., Lang B., Ramsay T., et al. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care Res (Hoboken) 2012, 64(1):122-131.
101. Saad C.G., Borba E.F., Aikawa N.E., et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011, 70(6):1068-1073.
102. Shinjo S.K., de Moraes J.C., Levy-Neto M., et al. Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease. Vaccine 2012, 31(1):202-206.
103. Marie I., Ménard J.F., Hachulla E., et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 2011, 41(1):48-60.
104. Efthimiou P., Pokharna H., Kukar M., et al. PCP chemoprophylaxis is essential for lymphopenic dermatomyositis patients treated with immunomodulators. Muscle Nerve 2011, 43(6):918-919.
105. Evans W.E., Hon Y.Y., Bomgaars L., et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. JClin Oncol 2001, 19(8):2293-2301.
106. Booth R.A., Ansari M.T., Loit E., et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011, 154(12):814-823.
107. Cherin P., Piette J.C., Wechsler B., et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. JRheumatol 1994, 21:1092-1097.
108. Danieli M.G., Malcangi G., Palmieri C., et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002, 61:37-41.
109. Patwa H.S., Chaudhry V., Katzberg H., et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012, 78(13):1009-1015.
110. Lam C.G., Manlhiot C., Pullenayegum E.M., et al. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis 2011, 70(12):2089-2094.
111. Danieli M.G., Pettinari L., Moretti R., et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011, 10(3):144-149.
112. Rowin J., Amato A.A., Deisher N., et al. Mycophenolate mofetil in dermatomyositis: is it safe?. Neurology 2006, 66(8):1245-1247.
113. Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52(2):601-607.
114. Noss E.H., Hausner-Sypek D.L., Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. JRheumatol 2006, 33(5):1021-1026.
115. Oddis C.V., Sciurba F.C., Elmagd K.A., et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999, 353(9166):1762-1763.
116. Cagnoli M., Marchesoni A., Tosi S. Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis. Clin Exp Rheumatol 1991, 9(6):658-659.
117. Oddis C.V., Reed A.M., Aggarwal R., et al. Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013, 65(2):314-324.
118. Valiyil R., Casciola-Rosen L., Hong G., et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010, 62(9):1328-1334.
119. Benveniste O., Drouot L., Jouen F., et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011, 63(7):1961-1971.
120. Rouster-Stevens K.A., Ferguson L., Morgan G., et al. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2013, [Epub ahead of print]. 10.1002/acr.22198.
121. Park J.K., Yoo H.G., Ahn D.S., et al. Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int 2012, 32(11):3587-3590.
122. Brunasso A.M., Scocco G.L., Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. JRheumatol 2010, 37(7):1549-1550.
123. Morganroth P.A., Kreider M.E., Werth V.P. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010, 62(10):1496-1501.
124. Kotani T., Takeuchi T., Makino S., et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 2011, 30(8):1021-1028.
125. Cavagna L., Caporali R., Abdì-Alì L., et al. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. JRheumatol 2013, 40(4):484-492.
126. Ogata A., Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol 2012, 2012:946048.
127. Arabshahi B., Silverman R.A., Jones O.Y., et al. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. JPediatr 2012, 160(3):520-522.
128. Musuruana J.L., Cavallasca J.A. Abatacept for treatment of refractory polymyositis. Joint Bone Spine 2011, 78(4):431-432.
129. Thompson B., Corris P., Miller J.A., et al. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. JRheumatol 2008, 35(10):2080-2082.
130. Reiff A., Shaham B., Weinberg K.I., et al. Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis. JClin Immunol 2011, 31(4):615-622.
131. Cooles F.A., Jackson G.H., Menon G., et al. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. Rheumatology (Oxford) 2011, 50(4):810-812.
132. Wang D., Zhang H., Cao M., et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis 2011, 70(7):1285-1288.
133. Varjú C., Pethö E., Kutas R., et al. The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil 2003, 17(1):83-87.
134. Mathiesen P.R., Ørngreen M.C., Vissing J., et al. Aerobic fitness after JDM-a long-term follow-up study. Rheumatology (Oxford) 2013, 52(2):287-295.
135. Alexanderson H., Stenström C.H., Jenner G., et al. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000, 29(5):295-301.
136. Alexanderson H. Exercise effects in patients with adult idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009, 21(2):158-163.
137. Nader G.A., Dastmalchi M., Alexanderson H., et al. Alongitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. Mol Med 2010, 16(11-12):455-464.
138. Chung Y.L., Alexanderson H., Pipitone N., et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 57(4):694-702.
139. Marie I., Hachulla E., Hatron P.Y., et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors. JRheumatol 2001, 28:2230-2237.
140. Bronner I.M., van der Meulen M.F., de Visser M., et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006, 65:1456-1461.
141. Ponyi A., Borgulya G., Constantin T., et al. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 2005, 44:83-88.
142. Limaye V., Hakendorf P., Woodman R.J., et al. Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J 2012, 42(2):191-198.
143. Airio A., Kautiainen H., Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006, 25:234-239.
144. Marie I., Hatron P.Y., Levesque H., et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999, 78:139-147.
145. Yamasaki Y., Yamada H., Ohkubo M., et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. JRheumatol 2011, 38:1636-1643.
146. Danko K., Ponyi A., Constantin T., et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004, 83:35-42.
147. Marie I., Hatron P.Y., Dominique S., et al. Short-term and long-term outcome of anti-Jo1-positive patients with Anti-Ro52 antibody. Semin Arthritis Rheum 2011, 41(6):890-899.
148. Griggs R.C., Askanas V., DiMauro S., et al. Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.